Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System
Retrieved on:
Tuesday, May 30, 2023
Technology, Mobile, Wireless, Packaging, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Transport, General Health, Internet, Electronic Design Automation, Data Management, Logistics, Supply Chain Management, Medical Supplies, Hypersensitivity, Approximation error, Rocuronium bromide, Risk, Neuromuscular blocking agents, Use, Fresenius (company), Hypotension, RFID, Magnesium, RAIN, ARC, Multimedia, Inhalation, Procainamide, Certification, Paralysis, Hypertension, Suxamethonium chloride, Hospital, Patient, Chloride, Patient safety, Anaphylaxis, Intubation, Quinidine, FDA, Relaxation, Caesarean section, Medication, Lithium, Warehouse, Medical device, Pharmaceutical industry, Medical imaging, Birth control, Death
Fresenius Kabi, a leading provider of injectable medications, announced today it has launched Rocuronium Bromide Injection with advanced RFID-enabled labels in the United States.
Key Points:
- Fresenius Kabi, a leading provider of injectable medications, announced today it has launched Rocuronium Bromide Injection with advanced RFID-enabled labels in the United States.
- Rocuronium Bromide Injection is part of Fresenius Kabi's +RFID™ portfolio of smart-labeled medications , designed to help enhance patient safety and support a more-efficient medication inventory process.
- Fresenius Kabi Rocuronium Bromide Injection +RFID is available direct from the company and U.S. wholesalers in a 50 mg per 5 mL multiple dose vial.
- This Important Safety Information does not include all the information needed to use Rocuronium Bromide Injection safely and effectively.